Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China; Clinical Laboratory, The Second People's Hospital of Wuhu City, Wuhu 241001, Anhui, People's Republic of China.
Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China.
Int Immunopharmacol. 2021 Jun;95:107553. doi: 10.1016/j.intimp.2021.107553. Epub 2021 Mar 23.
Epstein-Barr virus infection is closely related to the occurrence and development of a variety of malignant tumors. Tumor immunotherapy has been combined with modern biological high-tech technology, and has become the fourth cancer treatment mode after surgery, chemotherapy and radiotherapy. In 2013, immunotherapy was named the first of ten scientific breakthroughs by science. It aims to control and destroy tumor cells by stimulating and enhancing autoimmune function. In recent years, immune checkpoint inhibitors (ICIs) targeting PD-L1 have become a research hotspot in the field of cancer. Recent studies have shown that EBV infection can upregulate PD-L1 through complex mechanisms. Further understanding of these mechanisms and prevention of hyperprogressive disease (HPD) can make PD-L1 immune checkpoint inhibitors an effective way of immunotherapy for EBV related malignant tumors.
EB 病毒感染与多种恶性肿瘤的发生发展密切相关。肿瘤免疫治疗与现代生物高科技技术相结合，已成为继手术、化疗、放疗后的第四大肿瘤治疗模式。2013 年，免疫治疗被《科学》杂志评为十大科学突破之首。它旨在通过刺激和增强自身免疫功能来控制和破坏肿瘤细胞。近年来，针对 PD-L1 的免疫检查点抑制剂（ICIs）成为癌症领域的研究热点。最近的研究表明，EBV 感染可以通过复杂的机制上调 PD-L1。进一步了解这些机制并预防超进展性疾病（HPD）可以使 PD-L1 免疫检查点抑制剂成为 EBV 相关恶性肿瘤免疫治疗的有效方法。
